Brief: Ovid Therapeutics Q3 EPS USD -0.16
03/11/2023 12:00
Nov 03 (Reuters) - Ovid Therapeutics Q3 basic EPS USD -0.16. * Q3 net income USD -11.3 million * Q3 operating expenses USD 12.1 million
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors